{"filing":{"accession_number":"0001193125-26-385430","cik":"0002044725","ticker":"EVMN","company_name":"Evommune, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"evmn-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm"},"events":[{"id":32106,"run_id":29495,"accession_number":"0001193125-26-385430","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Evommune announced that its Phase 2b clinical trial of EVO756 in atopic dermatitis failed to meet primary and secondary endpoints across all doses studied. The company will cease development of EVO756 for atopic dermatitis but will continue evaluating EVO756 in migraine prophylaxis and advance its lead program EVO301 into Phase 2b for atopic dermatitis.","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35193,"accession_number":"0001193125-26-385430","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced top-line results from a Phase 2b clinical trial of EVO756 in atopic dermatitis that failed to meet its primary and secondary endpoints. The company disclosed it will not advance EVO756 in AD but will continue development in migraine prophylaxis, while advancing its lead program EVO301 into Phase 2b. This is a material clinical development milestone affecting the company's pipeline strategy and investor expectations, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific taxonomy type. It is a material operational/clinical event central to a biotech company's value proposition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:02:13.026910+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35194,"accession_number":"0001193125-26-385430","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced that its Phase 2b trial of EVO756 for atopic dermatitis \"did not meet the primary and secondary endpoints in any of the doses studied\" and the company \"plans to cease development of EVO756 for AD.\" This represents a material clinical development decision—discontinuation of a program—coupled with a strategic pivot to continue EVO756 evaluation in migraine prophylaxis and advance EVO301 as the lead AD program. While the disclosure includes clinical trial results, the salient event is the operational/strategic decision to halt one development program and reallocate resources, which would materially affect investor assessment of the company's pipeline and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:02:13.026910+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35193,"accession_number":"0001193125-26-385430","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced top-line results from a Phase 2b clinical trial of EVO756 in atopic dermatitis that failed to meet its primary and secondary endpoints. The company disclosed it will not advance EVO756 in AD but will continue development in migraine prophylaxis, while advancing its lead program EVO301 into Phase 2b. This is a material clinical development milestone affecting the company's pipeline strategy and investor expectations, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific taxonomy type. It is a material operational/clinical event central to a biotech company's value proposition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:02:13.026910+00:00","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-09-08"},{"id":35194,"accession_number":"0001193125-26-385430","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced that its Phase 2b trial of EVO756 for atopic dermatitis \"did not meet the primary and secondary endpoints in any of the doses studied\" and the company \"plans to cease development of EVO756 for AD.\" This represents a material clinical development decision—discontinuation of a program—coupled with a strategic pivot to continue EVO756 evaluation in migraine prophylaxis and advance EVO301 as the lead AD program. While the disclosure includes clinical trial results, the salient event is the operational/strategic decision to halt one development program and reallocate resources, which would materially affect investor assessment of the company's pipeline and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:02:13.026910+00:00","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-09-08"}]}